Connect with us

Technology

Aberdeen Multi-Market Income Fund (MMT) Announces 22% Increase in Monthly Distribution and Adoption of a Managed Distribution Policy

Published

on

PHILADELPHIA, July 10, 2026 /PRNewswire/ — The Board of Trustees of Aberdeen Multi-Market Income Fund (NYSE: MMT) has adopted a Managed Distribution Policy (“MDP”) for the Fund at an annualized rate equal to 11.00% of MMT’s average monthly net asset value.

The increase of the MDP results in a meaningful enhancement to the shareholder distribution rate, with the Fund’s monthly distribution increased from $0.0328 per share to $0.04 per share, representing a 22% increase over the prior distribution level. This higher payout reflects the Fund’s commitment to delivering consistent, competitive cash flow to shareholders.

The distribution under the new rate will be paid on July 31, 2026, to shareholders of record as of July 23, 2026 (ex-dividend date July 23, 2026). The increased distribution rate reflects both the Fund’s income-generating capability and the Board’s ongoing consideration of shareholder distributions.

Under the MDP, the Fund will pay monthly distributions at an annual rate, set once a year, that is a percentage of the average daily net asset value for the previous month-end prior to declaration date. Distributions under the MDP are expected to be derived from current income, and may be supplemented by net realized capital gains, if any, and, to the extent necessary, a return of paid-in capital.

Important Information

Shares of closed-end funds are listed for trading on national securities exchanges and are bought and sold in the secondary market. The market price of a fund’s shares is determined by supply and demand and may be greater than (a “premium”) or less than (a “discount”) the fund’s net asset value (NAV). A fund’s investment return and principal value will fluctuate, and investors may receive more or less than their original investment upon the sale of shares. There is no assurance that a fund will achieve its investment objective. Past performance is not indicative of future results.

The trading price of a closed-end fund’s shares may be influenced by various factors, including market conditions, investor sentiment, and other external forces, and is not directly controlled by the fund, its Board of Directors, or its investment adviser. As a result, shares may trade at a premium to or discount from NAV at any given time. A premium to NAV may not be sustained, and a discount to NAV may increase or decrease over time. Investors should consider these risks when purchasing or selling closed-end fund shares.

Shareholders whose fund shares trade at a premium to NAV and who participate in the fund’s dividend reinvestment plan should be aware that distributions may be reinvested at prices above NAV, which may adversely affect investment results.

The Fund’s policy is expected to provide a steady and sustainable cash distribution to Fund shareholders that may help reduce the Fund’s current discount to NAV. There is no assurance that a Fund will achieve these results. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the distributions or the terms of the Fund’s policy.

At the end of each calendar year, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of the fund’s distributions and provide information with respect to their appropriate tax treatment for the prior calendar year. You should not draw any conclusions about any of these Funds’ investment performance from the amount of the distributions.

Circular 230 disclosure: To ensure compliance with requirements imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.

About Aberdeen Investments

Aberdeen Investments Global is the trade name of Aberdeen’s investments business, herein referred to as “Aberdeen Investments” or “Aberdeen”. In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.

Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund’s investment return and principal value will fluctuate so that an investor’s shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund’s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results.

Aberdeen Investments is among the world’s largest asset managers, with decades of experience overseeing closed-end funds dating back to the 1980s. Closed-end funds represent a core component of Aberdeen Investments’ client franchise in both the U.S. and global markets. As of March 31, 2026, the firm had approximately $506 billion in assets under management, and Aberdeen and its affiliates managed 27 closed-end funds – 15 available in the U.S. and 12 outside the U.S. – totaling $25.6 billion in assets.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aberdeen-multi-market-income-fund-mmt-announces-22-increase-in-monthly-distribution-and-adoption-of-a-managed-distribution-policy-302822908.html

SOURCE Aberdeen Multi-Market Income Fund

Continue Reading

Technology

How Can Humanity Become Friends with the Ocean?

Published

on

By

BEIJING, Nov. 6, 2026 /PRNewswire/ — A news report from China.org.cn on China’s efforts in marine ecological governance:

“Look, white dolphins!” Such excited cries can often be heard along the coast of Xiamen, a city in east China’s Fujian Province.

The Indo-Pacific humpback dolphin, commonly known as the Chinese white dolphin, is considered Class I nationally protected wildlife in China. As apex predators in coastal waters, these dolphins are regarded as a barometer of marine ecosystem health. Back in the 1990s, however, rising shipping activity, coastal reclamation and near‑shore development severely encroached on their habitats.

To minimize disturbances to dolphin habitats, Xiamen established China’s first provincial‑level nature reserve dedicated to Chinese white dolphins in 1997. Since then, the city has continuously refined its coastal governance approaches, restricted activities with significant environmental impacts, and promoted cross‑regional collaboration in conservation. Many other ocean‑friendly initiatives have also been rolled out. These include restoring mangrove wetland ecosystems; implementing an “offshore sanitation” mechanism and organizing public beach‑clean‑up campaigns to regularly remove floating marine debris; and releasing nearly 8 billion aquatic animals across 18 species through stock enhancement programs. As a result, populations of several fish species, such as the wild large yellow croaker and yellowfin seabream, have returned to Xiamen Bay.

Recently, “AI bodyguards” have joined the conservation effort. High‑definition cameras, drones and intelligent recognition systems track dolphin activity round‑the‑clock. Automatic alerts are issued whenever vessels approach the dolphins in violation of regulations. Researchers have also created individual digital profiles for each dolphin, identifying them by their dorsal‑fin shapes and body spot patterns, while recording their movement trajectories.

Xiamen is a microcosm of China’s efforts in marine ecological governance — forging ahead boldly yet never walking alone.

Over the decades, China has taken a series of concrete steps: from founding its first marine nature reserve in 1963, to proposing the goal of “building a strong maritime nation,” and publishing the white paper “Marine Eco‑Environmental Protection in China”; from drawing marine ecological protection red lines, to actively engaging with the UN Decade of Ocean Science for Sustainable Development and signing major international agreements on marine conservation, including the UN Agreement on Biodiversity Beyond National Jurisdiction (UN BBNJ).

For decades, China has been answering a vital question through concrete action: how can humanity coexist harmoniously with the ocean and create mutual benefits?

The answer is becoming increasingly clearer. Today, China’s extensive coastline features clean waters and pristine beaches, with fish swimming freely and seabirds soaring overhead. Not long ago, China’s Blue Bay Restoration Initiative was named a UN World Restoration Flagship. Now, the 21st Xiamen World Ocean Week is officially inaugurated, bringing together experts, scholars and representatives from various countries and international organizations to discuss marine conservation and harmonious coexistence between humanity and the ocean. In marine ecological protection and governance, China is not only a proactive participant and practitioner, but also a contributor to sharing experience and shaping future approaches.

Along Xiamen’s shoreline, the sea breeze blows gently as children run after the waves, echoing the ongoing story of humanity and the ocean.

China Mosaic
http://www.china.org.cn/video/node_7230027.htm

View original content to download multimedia:https://www.prnewswire.com/news-releases/how-can-humanity-become-friends-with-the-ocean-302932059.html

SOURCE China.org.cn

Continue Reading

Technology

OneStream Surpasses 600 EMEA Customers and Triples AI Adoption

Published

on

By

OneStream triples AI customer base and deepens investment across EMEA as Founder and CEO Tom Shea presents governed Finance AI framework at Web Summit

LISBON, Portugal, Nov. 6, 2026 /PRNewswire/ — OneStream, the AI operating system for modern Finance that unifies core financial and operational processes, embedding the governance, context, and control required to make AI work for Finance, today announced it has surpassed 600 customers in EMEA and more than tripled its Finance AI customers in the region since the end of 2025. The news comes as Founder and CEO Tom Shea takes the stage at Europe’s biggest tech event, Web Summit 2026, to detail a framework for auditable, contextualized AI for Finance.

“CFOs across Europe are realizing the real advantage of AI isn’t the smartest model – it’s AI operating within a strict framework of financial governance,” said Tom Shea, Founder and CEO at OneStream. “AI is the reasoning engine, but enterprise software must be the trust engine. Our acceleration in EMEA proves leaders want a financial control tower that delivers answers they can act on without operational risk. We will continue investing heavily in the local teams and partners helping them build this secure foundation.”

Accelerating EMEA Momentum
Over the past 12 months, OneStream helped more than 100 new EMEA customers modernize their tech stack and passed 600 customers in the region, with customers in more than 35 markets. Customers span industries including manufacturing, retail, banking and financial services, pharmaceuticals, and oil and gas. Notable EMEA customers include Grupo ACS, Delivery Hero, and Swatch.

Customers across the region are using OneStream to modernize core Finance processes, replacing fragmented legacy systems with a unified platform for financial close, consolidation, reporting, and planning. This unified foundation helps teams keep pace with complex regulatory requirements across EMEA, while providing the governed data necessary to leverage AI for accelerated insights and real business value.

OneStream’s Finance AI adoption is growing alongside its broader platform growth. The number of EMEA customers using OneStream’s Finance AI has more than tripled since the end of 2025.

To support this sustained regional acceleration, OneStream continues to scale its operations and partner ecosystem, building on its established regional presence across London, Manchester, Paris, Amsterdam, and Madrid.

“Finance leaders across EMEA are modernizing their core Finance platforms to keep pace with complex regulation and move faster,” said Matt Rodgers, EVP, EMEA at OneStream. “That modernization is what enables them to take AI from pilots to enterprise-wide deployment, because it gives them a data foundation they can actually trust. Our momentum in the region underscores a fundamental shift toward governed, unified enterprise platforms that deliver real business value.”

Building Trust in AI Agents

Shea will appear in a featured fireside chat titled “Why AI and SaaS Need Each Other” on Thursday, Nov. 12, at 1:25 PM on Stage 7. Moderated by Hope King, Founder of Macro Talk, and featuring Luminance CEO Eleanor Lightbody, the session will examine the evolving role of enterprise software as AI agents take on increasingly complex workflows. Shea will detail how governed data, strict access controls, and transparent audit trails determine how safely organizations can let autonomous agents act on their own.

To learn more about Shea’s session at Web Summit, click here.

About OneStream

OneStream is the AI operating system for modern Finance that unifies core financial close, planning, and operational processes and data, in one intelligent platform, all embedded with the governance, context, and control required to make AI work for Finance.

With over 1,900 customers, including 16% of the Fortune 500, a strong ecosystem of go-to-market, implementation, and development partners and 1,600 employees, we empower the Office of the CFO to become a critical driver of business strategy and execution. To learn more, visit onestream.com.

Media Contact

Jaclyn Proctor
Media Relations Contact
OneStream
media@onestreamsoftware.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/onestream-surpasses-600-emea-customers-and-triples-ai-adoption-302931403.html

SOURCE OneStream, Inc.

Continue Reading

Technology

Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research

Published

on

By

CAMBRIDGE, Mass., Nov. 6, 2026 /PRNewswire/ — Insilico Medicine, a clinical-stage generative AI drug discovery company, today announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si, in collaboration with leading geroscience researcher David Sinclair from Harvard Medical School. Developed for the Grok Bot platform, PLSI is an open-source, multi-agent AI system designed to unify fragmented personal health records, track biological analysis, formulate personalized lifestyle interventions, predict and score post-intervention biomarker changes, as well as drive communal AI-powered geroscience research.

For decades, health management and longevity medicine have been hampered by severe data fragmentation. Laboratory blood panels, continuous glucose monitoring, wearable streams, epigenetic assays, and clinical records sit across disconnected portals, leaving patients unable to follow their biological trajectory and clinicians working from incomplete histories. Modern healthcare turns to LLMs to close that gap, however, without persistent, auditable memory or follow-up on if advice actually improves outcomes, they rarely outperform traditional methods.

Personal Longevity Superintelligence (PLSI) addresses this gap with a continuous, 24/7 automated research loop. It converts fragmented medical data into a standardized longitudinal health trajectory and generates accountable, predictive guidance through a multi-agent architecture. The system continuously forecasts health risks, proposes interventions, and scores outcomes through closed-loop feedback.

Running within Grok Bot’s secure environment, it coordinates a team of up to 30 specialized AI agents, standardizes heterogeneous records with clinical coding systems such as LOINC, RxNorm, and UCUM, and uses always-on routines to monitor longevity science updates, organize incoming data, and keep the personal health state current without constant re-prompting. The same system is framed for three complementary roles:

As a personal longevity assistant, PLSI turns scattered labs, wearables, epigenetic assays, and clinical files into a unified, audit-ready health trajectory on the user’s device. It proposes lifestyle, nutritional, or longevity interventions with an auditable “prediction card” (target biomarker, confidence interval, time horizon, and evidence grade), evaluates each plan through an agent-driven adversarial review. When follow-up results arrive, PLSI scores whether outcomes fall within the predicted interval, confirms direction, and tracks calibration over time, turning each choice into a checkable N-of-1 experiment. Users can also voluntarily allocate unused daily token quota to Idle Research in the background to find new ways to increase their lifespan.

As a physician’s assistant, PLSI supplies structured longitudinal context instead of fragmented PDFs and portal exports. Standardized representations and a coherent biological trajectory help clinicians better organize their workflow Prediction cards and evidence grades aid in decision-making, while closed-loop scoring after follow-up supports auditable discussion of response and adherence. PLSI also features safeguards that overrule AI discretion to keep  formal diagnosis and prescriptions solely with licensed physicians.

As a partner for aging research, PLSI extends individual tracking into communal discovery. Users may opt in to contribute consented, deidentified trajectories to Longevity Mothership via an anonymous relay with an irrevocable kill switch to purge records on demand. Idle Research is a modern take on volunteer computing platforms , such as Folding@home, which let autonomous researcher agents scan literature, formulate hypotheses, and design analyses based on  public databases to accelerate target discovery and other anti-aging discovery activities.

Across all three roles, privacy is the default: a zero-trust architecture keeps raw medical files and identifiable clinical records in the user’s environment , unless the user explicitly opts into communal research. Both the PLSI Client and the Longevity Mothership backends are fully open-source and freely available on GitHub for review and contribution. Both setups feature data controller agents, which scrub the data at egress and intake points to prevent entry re-identification.

PLSI is available to all Grok Bot users and can be installed by instructing your bot with the following one-liner:

Set yourself up using https://github.com/Insilico-org/plsi 

The agentic skills and code are provided as an open-source package which can be inspected and modified by all, according to their needs.

“Longevity Grok turns Grok Bot into an open platform where individuals, physicians, and scientists can use AI to better understand their health, predict the effects of interventions, and find ways to live longer, healthier lives,” said David A. Sinclair, Ph.D., Professor of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. “What makes this exciting is that people can contribute to scientific discovery while improving their own health, helping us understand why we age and how we might slow or even reverse it.”

“Currently, there are zero tools that are clinically proven to give a healthy person an additional year of life if they are already dieting, exercising, sleeping, and getting regular diagnostics,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. “Longevity Grok is a distributed system designed around a personal research space where you can work with your own data to optimize your health, longevity, and peak-span trajectories. As this system diffuses into the community, we expect to achieve longevity superintelligence, enabling a vast network of individuals to conduct autonomous research on their own biology while utilizing shared computation resources to pursue advanced longevity experiments. Aging is the only inescapable constraint on human freedom, and pushing this frontier is about giving people the optionality to remain young, healthy, and productive for as long as possible.”

Longevity has been central to Insilico’s mission since its inception. The company’s path drew industry attention in 2015 at the NVIDIA GTC conference, where Alex Zhavoronkov, Ph.D., founder and CEO of Insilico, challenged the tech world with a provocative question: “Can NVIDIA cure aging?” In 2014, Insilico established the annual Aging Research and Drug Discovery (ARDD) meeting, now widely regarded as a leading academic gathering for geroscience and biogerontology. The 13th ARDD, held at Harvard University in 2026, brought together leading academic investigators, pharmaceutical executives, and clinical pioneers to translate longevity discoveries into actionable medicine.

In 2026, Insilico accelerated the translation of AI-driven longevity research from experimental theory to transformative biological interventions. In April, the company announced the industry’s first longevity board of high-profile scientists, chaired by Andrew Adams, Ph.D., Group Vice President of Molecular Discovery at Eli Lilly and Company, to advance AI-driven aging research for drug discovery. In September, Insilico open-sourced an AI longevity toolkit, including LongevityBench, Longevity-LLMs, and LongevityClaw, with collaborators in a Cell cover study, accelerating research and therapeutic development. That publication follows Insilico’s contemporaneous Nature Biotechnology paper, in which Rentosertib, the company’s most advanced AI-driven pipeline candidate, showed biological age reversal according to Phase IIa clinical data across six independent proteomic aging clocks.

Since 2014, Insilico has published more than 50 research papers on aging and longevity, aging biomarkers, therapeutic targets, and therapeutics implicated in aging, longevity, and disease.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

For more information, please visit www.insilico.com

View original content:https://www.prnewswire.com/news-releases/insilico-open-sources-247-personal-longevity-superintelligence-to-turn-quantified-self-data-into-predictive-health-states-and-aging-research-302931941.html

SOURCE Insilico Medicine

Continue Reading

Trending